Furthermore, liver-specific knockout of Sptbn1 (βS-LSKO) or siRNA targeting βII-spectrin reduces diet-induced Metabolic Dysfunction Associated Steatohepatitis (MASH) and protects against HCC [29], suggesting that targeting βII-spectrin in experimental studies might provide new insights into MASH and steatosis-associated HCC. This evidence concerns the gene SPTBN1 and steatosis.